Showing results (151-160 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|November 22, 2013
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumorsD S Hong, R Kurzrock, A Naing, et al.
Investigational New Drugs|March 16, 2021
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutationsJii Bum Lee, Minkyu Jung, Seung Hoon Beom, et al.
Investigational New Drugs|November 27, 2021
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapyMeng Zhang, Lijuan Gao, Yiping Ye, et al.
Investigational New Drugs|January 27, 2021
Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysisBo Chen, Donghong Sun, Xiuni Qin, et al.
Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Investigational New Drugs|February 10, 2021
Dissociated response and clinical benefit in patients treated with nivolumab monotherapyYuki Sato, Takeshi Morimoto, Shigeo Hara, et al.
Investigational New Drugs|February 9, 2021
Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomingsMasahiro Wada, Akihiko Ozaki, Takashi Miyachi, et al.
Investigational New Drugs|March 1, 2021
Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibitionYuqiang Hu, Ming Hao, Chang Zhong, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Investigational New Drugs|February 7, 2017
State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261Karl J Föhr, Uwe Knippschild, Anna Herkommer, et al.
Pageof 372